Literature DB >> 15896463

A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC family from Southern Italy.

Francesco Baudi1, Giuseppina Fersini, Annamaria Lavecchia, Rosa Terracciano, Francarlo Leone, Barbara Quaresima, Maria C Faniello, Loredana De Paola, Patrizia Doldo, Giovanni Cuda, Francesco Costanzo, Salvatore Venuta.   

Abstract

Germline mutations within the mismatch repair (MMR) genes are generally found in colorectal cancer (CRC) patients with a positive family history for the presence of the neoplasia. Clinical standard criteria have been established to define hereditary-non-polyposis-colorectal cancer (HNPCC)-prone families. Interestingly, the number of MMR gene mutations found in kindreds not fulfilling these criteria is still increasing. In this work we report the identification of a novel germline mutation of the hMSH2 gene, in two CRC-bearing subjects. The two probands belong to a large kindred from South Italy with no history suggestive for cancer aggregation. On the other hand, the early-onset of the neoplasia as well as the presence of a high number of tumor infiltrating lymphocytes (TILs) in the histological specimens of both patients, prompted us to perform a comprehensive genetic analysis. This analysis included the evaluation of the microsatellite instability (MSI) status with five markers according to the National Cancer Institute recommendations, followed by direct sequencing of the hMLH1 and hMSH2 genes. Both probands were found to carry a germline missense (277 C>T) mutation leading to the change (L93F) of an amino acid residue in a highly conserved domain of the MSH2 protein. This mutation is accompanied by the loss of expression of the hMSH2 gene in the tumor tissue. Our findings suggest that in the presence of the above-mentioned criteria it may be useful to perform a molecular analysis of the MMR genes, even if the pedigree does not show marked aggregation of cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15896463     DOI: 10.1016/j.canlet.2004.09.051

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.

Authors:  Mev Dominguez Valentin; Felipe Carneiro da Silva; Erika Maria Monteiro dos Santos; Bianca Garcia Lisboa; Ligia Petrolini de Oliveira; Fabio de Oliveira Ferreira; Israel Gomy; Wilson Toshihiko Nakagawa; Samuel Aguiar Junior; Mariana Redal; Carlos Vaccaro; Adriana Della Valle; Carlos Sarroca; Dirce Maria Carraro; Benedito Mauro Rossi
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer.

Authors:  Kristen M Drescher; Poonam Sharma; Patrice Watson; Zoran Gatalica; Stephen N Thibodeau; Henry T Lynch
Journal:  Fam Cancer       Date:  2009-01-23       Impact factor: 2.375

3.  Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries.

Authors:  Erika Maria Monteiro Santos; Mev Dominguez Valentin; Felipe Carneiro; Ligia Petrolini de Oliveira; Fabio de Oliveira Ferreira; Samuel Aguiar Junior; Wilson Toshihiko Nakagawa; Israel Gomy; Victor Evangelista de Faria Ferraz; Wilson Araujo da Silva Junior; Dirce Maria Carraro; Benedito Mauro Rossi
Journal:  BMC Cancer       Date:  2012-02-09       Impact factor: 4.430

4.  Report of a Novel Mutation in MLH1 Gene in a Hispanic Family from Puerto Rico Fulfilling Classic Amsterdam Criteria for Lynch Syndrome.

Authors:  Juan M Marqués-Lespier; Yaritza Diaz-Algorri; Maria Gonzalez-Pons; Marcia Cruz-Correa
Journal:  Gastroenterol Res Pract       Date:  2014-10-20       Impact factor: 2.260

5.  Deficiency of hMLH1 and hMSH2 expression is a poor prognostic factor in Early Gastric Cancer (EGC).

Authors:  Xueru Zhu; Yiwei Wang; Hongjia Li; Wenji Xue; Ruifen Wang; Lifeng Wang; Meiling Zhu; Leizhen Zheng
Journal:  J Cancer       Date:  2017-06-01       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.